Targeting Phantom Pain with Psilocybin: Toward Integration with Adaptive Sensory Technologies
ACS Medicinal Chemistry Letters – April 10, 2025
Source: OpenAlex
Summary
Psilocybin offers a clinically meaningful reduction in phantom and residual limb pain, marking a significant advance in Pain Management and Physical Medicine and Rehabilitation. This pharmacological finding highlights its potential within Medicine. Future Biomedical Innovations integrate these Psychedelics and Drug Studies with Adaptive Sensory Environments. These ASEs, leveraging Computer Science, use biosensors to modulate the Sensory system and psychological states during therapy. This approach aims for precision and scale in interventions, prompting considerations for Neuroethics and Human Enhancement in optimizing therapeutic benefits.
Abstract
Psilocybin demonstrates a clinically meaningful reduction in phantom and residual limb pain. Adaptive sensory environments (ASEs) separately offer biosensor-guided modulation of psychological states during psychoactive therapy. This Patent Highlight explores the pharmacological findings of a psilocybin trial and discusses future integration with ASE systems to precision and scale psychedelic-assisted interventions.